Basiliximab: a review of its use as induction therapy in renal transplantation.
about
Monoclonal antibody therapy and renal transplantation: focus on adverse effectsBiologics in organ transplantationConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsSolid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies.Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation.Early monitoring of the human polyomavirus BK replication and sequencing analysis in a cohort of adult kidney transplant patients treated with basiliximab.Medical applications of leukocyte surface molecules--the CD moleculesReduced progression of cardiac allograft vasculopathy with routine use of induction therapy with basiliximabManagement and prevention of post-transplant malignancies in kidney transplant recipientsTransplant-related immunosuppression: a review of immunosuppression and pulmonary infectionsInterleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesInfectious complications associated with monoclonal antibodies and related small moleculesThe importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus.Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose.Current status of immunosuppressive agents for solid organ transplantation in children.Malignancies after pediatric kidney transplantation: more than PTLD?Basiliximab: efficacy and safety evaluation in kidney transplantation.The expanding role of therapeutic antibodies.Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.Effectiveness of an Evidence-Based Induction Therapy Protocol Revision in Adult Kidney Transplant Recipients.Renal transplant immunology in the last 20 years: A revolution towards graft and patient survival improvement.Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.Effects of interleukin 2 receptor blockers on patient and graft survival in renal-transplanted children.The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?The role of basiliximab in the evolving renal transplantation immunosuppression protocol.Analysis of Risk Factors for Kidney Retransplant Outcomes Associated with Common Induction Regimens: A Study of over Twelve-Thousand Cases in the United States.Long-term outcome of ATG vs. Basiliximab induction.Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival.
P2860
Q26826880-F14C701C-72A5-4F56-AAAD-F8C00AD9C813Q26829578-95BD3668-4D67-47AE-B0FD-C8EF98F7A584Q26830569-BC02D552-8192-4B51-83CD-8FEDF9B84F91Q30316796-F3B40E40-4F7E-4B20-B937-EC557B47ED66Q33905617-FA4C6A31-4064-4668-A40B-B1DF2F525BA3Q35232066-328664DF-9C05-4069-A8F0-13C159793DF4Q35690889-041385AE-10FE-4736-9F03-ECA89D251736Q36024257-19CF9A30-A63B-42C6-8023-D50280FAC496Q36088854-1FBE7B3C-ED6B-48C6-B4D9-83CDD14C3BEEQ36328703-322D1A54-BE6F-4842-853F-6866B4921B80Q36505748-26011960-8046-4726-9576-4B8423C74F91Q36724093-02651472-6005-4FDE-8FD8-B4A887AAD239Q37156636-AD97C05F-4540-438E-9D2D-9418F5E4038FQ37877294-8B791583-3840-4DA3-9EA4-080ADA813CB7Q37982854-1ED3E655-1C3C-4F83-97D5-0439A145E66EQ37987565-ABF2D166-8237-4E85-9E5B-CDEBB03611E0Q38141838-BA931DB0-26CD-4182-841E-D97E75C98E3CQ38165224-09DAC3BC-6632-4E5B-B70E-4CB362E1960EQ38182645-F2B22E8F-F811-42F4-9ED9-8B5FA13F76BCQ38614123-B5027C0B-2BC8-4DF3-9307-36954C2E2BCEQ38802439-CA851661-D896-434E-8040-8AF685EB8672Q38967258-2F2077C2-5951-43D0-8E13-67D88DC838A1Q39037933-1C7A76EB-7BE6-4D8F-8965-2812C2ACDD74Q41475881-092B2AFB-2507-499E-A20F-0F3A2EF1B880Q41774477-9BA17221-D475-46B4-98F9-D48B0978EB00Q43078141-ED4A1977-8165-4B7E-852B-03C859631014Q47193453-9D138426-D8B9-4B0B-A1D2-3A95091E027EQ52897493-07F9C3EC-D69A-4432-B95E-94962B696A89Q54345873-3A2B3A34-BB5E-4574-81D4-C19BF90EE698
P2860
Basiliximab: a review of its use as induction therapy in renal transplantation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Basiliximab: a review of its use as induction therapy in renal transplantation.
@ast
Basiliximab: a review of its use as induction therapy in renal transplantation.
@en
type
label
Basiliximab: a review of its use as induction therapy in renal transplantation.
@ast
Basiliximab: a review of its use as induction therapy in renal transplantation.
@en
prefLabel
Basiliximab: a review of its use as induction therapy in renal transplantation.
@ast
Basiliximab: a review of its use as induction therapy in renal transplantation.
@en
P1433
P1476
Basiliximab: a review of its use as induction therapy in renal transplantation.
@en
P2093
Therese M Chapman
P304
P356
10.2165/00003495-200363240-00009
P577
2003-01-01T00:00:00Z
P6179
1025746439